Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.88)
# 403
Out of 4,444 analysts
478
Total ratings
61.8%
Success rate
21.7%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Rated: Hold | $105 | $108.46 | -3.19% | 35 | Jun 23, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | n/a | $99.87 | - | 22 | Jun 23, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | n/a | $122.15 | - | 21 | Jun 22, 2026 | |
| EWTX Edgewise Therapeutics | Maintained: Buy | n/a | $42.30 | - | 34 | Jun 17, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $70 | $48.40 | +44.63% | 9 | Jun 15, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | n/a | $1,117.26 | - | 35 | Jun 8, 2026 | |
| AVAH Aveanna Healthcare Holdings | Reiterated: Hold | n/a | $8.47 | - | 1 | Jun 8, 2026 | |
| ALT Altimmune | Maintained: Buy | n/a | $2.95 | - | 3 | May 29, 2026 | |
| IVA Inventiva | Reiterated: Buy | n/a | $3.46 | - | 3 | May 29, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $709 → $514 | $509.76 | +0.75% | 13 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $6.03 | +99.00% | 12 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.92 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $32.63 | - | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $10.08 | +9.18% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $106 | $81.20 | +30.54% | 37 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $55.00 | - | 21 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $8.05 | +24.22% | 15 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.28 | - | 7 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $36.05 | - | 5 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3402 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $52.33 | - | 29 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $351.43 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $103.46 | +106.84% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $19.30 | +19.17% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $623.43 | +30.25% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $101.87 | -17.54% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.52 | - | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $199.59 | -28.85% | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.25 | - | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $120.60 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.04 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $234.89 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.64 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $58.16 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $3.85 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.00001 | n/a | 7 | Mar 20, 2023 |
Incyte
Jun 23, 2026
Rated: Hold
Price Target: $105
Current: $108.46
Upside: -3.19%
Kymera Therapeutics
Jun 23, 2026
Maintained: Buy
Price Target: n/a
Current: $99.87
Upside: -
Protagonist Therapeutics
Jun 22, 2026
Maintained: Buy
Price Target: n/a
Current: $122.15
Upside: -
Edgewise Therapeutics
Jun 17, 2026
Maintained: Buy
Price Target: n/a
Current: $42.30
Upside: -
MBX Biosciences
Jun 15, 2026
Reiterated: Buy
Price Target: $70
Current: $48.40
Upside: +44.63%
Eli Lilly and Company
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $1,117.26
Upside: -
Aveanna Healthcare Holdings
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $8.47
Upside: -
Altimmune
May 29, 2026
Maintained: Buy
Price Target: n/a
Current: $2.95
Upside: -
Inventiva
May 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.46
Upside: -
Madrigal Pharmaceuticals
May 26, 2026
Reiterated: Buy
Price Target: $709 → $514
Current: $509.76
Upside: +0.75%
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $6.03
Upside: +99.00%
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $10.92
Upside: -
May 8, 2026
Maintained: Buy
Price Target: n/a
Current: $32.63
Upside: -
May 8, 2026
Reiterated: Buy
Price Target: $11
Current: $10.08
Upside: +9.18%
May 6, 2026
Reiterated: Buy
Price Target: $106
Current: $81.20
Upside: +30.54%
May 1, 2026
Maintained: Buy
Price Target: n/a
Current: $55.00
Upside: -
May 1, 2026
Maintained: Hold
Price Target: $10
Current: $8.05
Upside: +24.22%
Apr 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.28
Upside: -
Apr 20, 2026
Maintained: Buy
Price Target: n/a
Current: $36.05
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.3402
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $52.33
Upside: -
Nov 5, 2025
Maintained: Hold
Price Target: n/a
Current: $351.43
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $103.46
Upside: +106.84%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $19.30
Upside: +19.17%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $623.43
Upside: +30.25%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $101.87
Upside: -17.54%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.52
Upside: -
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $199.59
Upside: -28.85%
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.25
Upside: -
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $120.60
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $24.04
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $234.89
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $1.64
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $58.16
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $3.85
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.00001
Upside: n/a